Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ON long-term extension of oral BI 1015550 in IPF and PPF
CTR20242619Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nerandomilast in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Started Sep 2024; status: active.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on CTR20242619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242619.